Key facts
- It has raised $6.0M; the latest was Seed Round ($6.0M) in Apr 2026.
- Notable investors include Rare Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for The Protocole
- ·The full record, as it builds
Funding rounds
No funding rounds for The Protocole are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About The Protocole
Provider of clinician-guided peptide wellness prescriptions intended to offer cognitive support, body composition, and recovery. The company offers physician-led protocols built around medical-grade peptides sourced from compounding pharmacies, combining clinical oversight, safety review, curated membership access, and structured care pathways, enabling members to access peptide-based wellness prescriptions in a regulated, transparent, and clinically supervised manner.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- theprotocole.com/
- Ownership
- Privately Held (backing)
The Protocole doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in The Protocole shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on The Protocole in its N-PORT filings yet. We sweep new filings monthly.